Drug intelligence / Profile preview

OM-85-IN

Development stage: Phase 4
Lead developer: OM Pharma
Modality: Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Whole Cell Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration: Intranasal

Overview

OM-85-IN is a specific formulation of OM-85, a lyophilized bacterial lysate derived from 21 strains of 8 common respiratory pathogenic microorganisms. It functions as an immunomodulator, stimulating both innate and adaptive immune responses. The drug is being investigated for its safety, tolerability, and pharmacodynamics, particularly in patients with mild allergic asthma. Its mechanism involves modulating the immune system, enhancing epithelial barrier function, and inducing immune tolerance.

Brand names: Broncho-VaxomBroncho-MunalOmmunalPaxoralVaxoral
Other names: bacterial lysatebacterial extract

Targets

TLR (Toll-like receptors)

Beyond the preview

Go deeper on OM-85-IN.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OM-85-IN.

Explore the full profile